Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2013 on request of the Sponsor.
On 18 October 2000, orphan designation (EU/3/00/007) was granted by the European Commission to Orphan Europe SARL, France, for n-carbamyl-l-glutamic acid for the treatment of n-acetylglutamate synthetase (NAGS) deficiency.
N-carbamyl-l-glutamic acid treatment of N-acetylglutamate synthetase (NAGS) deficiency has been authorised in the EU as Carbaglu since 24 January 2003.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of N-acetylglutamate synthetase (NAGS) deficiency
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.